Alliance for Cancer Gene Therapy | Strategic Alliance Partners

In March 2024, the FDA approved the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) as a treatment for relapsed or resistant chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

In February 2024, the FDA approved a tumor-infiltrating lymphocyte therapy called lifileucel for people with advanced melanoma.

Funding from ACGT will help Chiocca perform FDA-required studies on mice to show the oncolytic virus is safe and can be manufactured for humans. It is the second such grant awarded to Chiocca from ACGT.

ACGT is advancing cell and gene therapy research for pancreatic tumors and other types of cancer.

Take a look back at the 2023 conference, hosted by the University of Calgary and McMaster University, and held in Banff, Alberta, Canada.

October is National Breast Cancer Awareness Month, and thus serves as an additional moment to point to the progress made in cell and gene therapy development, as well as the lingering challenges.

The term “immunotherapy” has quite a wide scope in cancer treatment. A lot of different therapies fall within the umbrella of immunotherapy, and two of the most successful are CAR T-cell therapies and immune checkpoint inhibitors.

Stephen Gottschalk, MD, is using grant funding from ACGT to develop CAR T-cell therapy to treat children with sarcomas. He spoke about the challenges of treating sarcomas, the need for new therapies, and the importance of ACGT.

ACGT recently awarded a half-million dollar grant to brain cancer researcher Juan Fueyo, MD, who is developing an oncolytic virus therapy to treat the brain cancer glioblastoma.

September is Childhood Cancer Awareness Month, serving as a chance to assess what progress has been made in advancing cell and gene therapy research for children with cancer.

Alliance for Cancer Gene Therapy (ACGT) awarded The Edward Netter Leadership Award to Crystal Mackall, MD, of Stanford University.

Alliance for Cancer Gene Therapy (ACGT) recently hosted their 2023 Summit, a scientific gathering of cancer experts to discuss challenges and opportunities with cell and gene therapy.

May is Brain Cancer Awareness Month, and the ACGT is raising awareness of the potential of the human immune system when combined with cell and gene therapy to defeat brain tumors.

The barrier is an essential part of keeping the brain safe, but it also prevents the immune system from eliminating brain cancer tumors.

Crystal Mackall, MD, an Alliance for Cancer Gene Therapy scientist, is helping create a remote-control technology to personalize CAR T-cell therapy for each cancer patient.